PolicyRSSToday
President Trump signed an executive order on April 18 directing the federal government to speed up access to treatments for serious mental illness, including conditions that are hard to treat. This means the FDA and other health agencies will work faster to get new mental health treatments to patients who need them.
WHY IT MATTERSPatients with treatment-resistant mental illness conditions may gain faster access to new therapies through streamlined FDA review processes and accelerated approval pathways.
AdvocacyRSS2 days ago
A patient with MS shares their personal experience of why starting treatment quickly with the most powerful available medications is worth it to them. They believe the benefits of aggressive, early treatment outweigh the potential side effects. This is one patient's perspective on MS treatment strategy.
WHY IT MATTERSThis patient perspective highlights the real-world decision-making that people with MS face when choosing between starting strong treatments early versus waiting, which can help other newly diagnosed patients think through their own treatment conversations.
AdvocacyRSS2 days ago
A parent shares their experience with their son's delayed diagnosis of thymidine kinase 2 deficiency (TK2d), a rare genetic disorder affecting how the body uses certain building blocks for DNA. The article highlights how early genetic testing could have identified the condition sooner and made a significant difference in the child's care and outcomes. Early testing is important because it allows doctors to start treatment and management strategies before serious complications develop.
WHY IT MATTERSParents of children with unexplained developmental delays or muscle weakness can use this story to advocate for early genetic testing with their doctors, potentially catching TK2d before irreversible damage occurs.
AdvocacyRSS2 days ago
A patient with von Willebrand disease shares how much they depend on Humate-P, a medication made from donated plasma. The article highlights how plasma donors' generosity directly impacts the lives of people who need plasma-derived treatments to stay healthy and safe.
WHY IT MATTERSPatients relying on plasma-derived therapies like Humate-P depend on a consistent supply of donated plasma — understanding this connection may inspire more people to become plasma donors and help secure treatment availability.
AdvocacyRSS2 days ago
This article uses the excitement of NASA's Artemis II space mission as inspiration to encourage big dreams about finding a cure for pulmonary hypertension, a serious lung disease that affects blood vessels. The author draws a parallel between humanity's ability to reach for the stars and the hope that patients with pulmonary hypertension should have for breakthrough treatments. The piece is motivational rather than reporting on specific medical news or research developments.
WHY IT MATTERSThis article may resonate emotionally with pulmonary hypertension patients by framing their disease journey within a larger narrative of human achievement and possibility, though it does not announce any new treatments, trials, or clinical developments.
AdvocacyRSS2 days ago
Three organizations that work with facioscapulohumeral muscular dystrophy (FSHD) patients are joining together to make clinical trials better. FSHD is a rare muscle disease that causes weakness in the face, shoulders, and upper arms. This partnership wants to improve how these trials are designed so they can test new treatments more effectively.
WHY IT MATTERSBetter-designed clinical trials mean faster progress toward treatments for FSHD, and patient input through the FSHD Society ensures trials are structured in ways that actually work for people living with the disease.
AdvocacyRSS2 days ago
A patient-led nonprofit called The Speak Foundation has created a network of specialized clinics called LGMD Centers of Excellence to help people with limb-girdle muscular dystrophy (LGMD), a rare muscle disease. This new network aims to solve a major problem: patients with LGMD have had trouble getting consistent care and doctors have struggled to develop new treatments because the patient population is very small and spread out.
WHY IT MATTERSThis coordinated clinic network could help LGMD patients access specialized care in one place and speed up the development of new treatments by making it easier for researchers to find and study patients.
PolicyRSSApr 16
The FDA is inviting companies that make testosterone replacement therapy drugs to apply for approval of a new use: treating low sex drive in men with a specific condition called idiopathic hypogonadism (when the body doesn't make enough testosterone for unknown reasons). This is an early step that could lead to new treatment options for men with this condition.
WHY IT MATTERSMen with idiopathic hypogonadism who experience low libido may soon have an FDA-approved treatment option specifically designed for this symptom, rather than relying on off-label use of existing testosterone therapies.
PolicyRSSApr 14
The FDA released new guidelines to help companies develop gene therapy treatments that use genome editing—a technology that can fix or change faulty genes. These guidelines explain what safety information and testing companies need to provide before the FDA will approve their treatments. This is meant to make it clearer and faster for companies to develop new gene therapies for patients with genetic diseases.
WHY IT MATTERSThis guidance establishes the regulatory pathway that will determine which genome editing therapies can reach patients, potentially accelerating approval timelines for rare genetic diseases currently lacking treatment options.
PolicyRSSApr 13
The FDA sent reminders to over 2,200 companies and research groups telling them they must share their clinical trial results on a public website called ClinicalTrials.gov. This is a requirement, not optional. The FDA is making sure that information about how medical treatments work—whether they help patients or cause problems—gets shared publicly so everyone can see the results.
WHY IT MATTERSWhen companies hide negative trial results, patients may not know the full picture about whether a treatment actually works, which could affect decisions about whether to participate in a trial or use a medication.
PolicyRSSApr 3
The FDA released new guidelines to help drug companies test medicines using human-based methods instead of animal testing. These new testing approaches could make it faster and safer to develop drugs by using data that better reflects how humans respond. This is part of the FDA's effort to bring effective treatments to patients more quickly.
WHY IT MATTERSPatients with rare diseases could gain access to new treatments faster if drug developers can use these human-centered testing methods instead of spending years on animal studies.
PolicyPUBMEDApr 1
Researchers compared how quickly rare disease drugs become available in China versus the United States between 2001 and 2024. The study looked at a problem called 'drug loss' — when medicines are approved in the US but never reach Chinese patients — and 'drug lag' — when there's a long delay before Chinese approval. The findings help the Chinese government understand what's blocking patients from getting treatments that already exist elsewhere in the world.
WHY IT MATTERSIf you have a rare disease in China, this research directly impacts whether you can access treatments that may already be approved and available in the United States, potentially identifying barriers your doctor or patient advocacy groups can help address.
AdvocacyRSSMar 26
NORD, a major rare disease organization, is partnering with OpenEvidence to create AI-powered tools that help doctors and patients find reliable information about rare diseases. This partnership aims to make it easier for people worldwide to access trustworthy resources about their conditions and treatment options.
WHY IT MATTERSThis partnership could help patients with rare diseases get faster access to accurate, expert-reviewed information from their doctors, potentially reducing diagnostic delays and improving treatment decisions.
PolicyPUBMEDMar 26
Scientists and doctors are saying that the system for developing and selling medicines for rare diseases needs improvement. New discoveries in genetics have helped create targeted treatments, but these medicines are often very expensive and hard to access. The article calls on researchers, doctors, and other groups to work together to make rare disease medicines more affordable and available to patients who need them.
WHY IT MATTERSIf you or a loved one has a rare disease, this research highlights why medicines for your condition may be expensive or hard to get — and pushes for systemic changes that could improve your access to treatment options.